ibritumomab tiuxetan

Ibritumomab tiuxetan is a monoclonal antibody radioimmunotherapy used primarily for the treatment of B-cell non-Hodgkin lymphoma. It consists of the murine IgG1 monoclonal antibody ibritumomab covalently bound to the chelating agent tiuxetan, which allows for stable binding of radioactive isotopes such as yttrium-90 or indium-111. The drug targets the CD20 antigen found on normal and malignant B lymphocytes. Upon binding to CD20, it delivers targeted radiation to B cells via its radiolabeled component (primarily yttrium-90), resulting in cell death through direct radiation damage and immune-mediated mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. Ibritumomab tiuxetan was developed by IDEC Pharmaceuticals (now part of Biogen Idec) and was first approved by the FDA in 2002 for relapsed or refractory low-grade or follicular B-cell non-Hodgkin lymphoma, with expanded indications later granted[1][5][6][8].

Brand names

Zevalin

Other names

ibritumomab tiuxetan90Y-ibritumomab